Geoffrey D. Mowatt, Partner with DLA Piper (Canada) LLP to Speak at The Knowledge Group’s Biosimilars Regulatory and Legal Challenges: A Look Back and What’s Ahead
New York, NY, November 22, 2016 --(PR.com)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Geoffrey D. Mowatt, Partner with DLA Piper (Canada) LLP will speak at The Knowledge Group’s webcast entitled: “Biosimilars Regulatory and Legal Challenges: A Look Back and What’s Ahead.” This event is scheduled for December 8, 2016 from 12:00pm – 2:00pm (ET).
For further details, please visit: https://theknowledgegroup.org/event-homepage/?event_id=2001
About Geoffrey D. Mowatt
Geoffrey Mowatt is certified by the Law Society of Upper Canada as a Specialist in Patent Law. His practice encompasses all areas of intellectual property law, with a focus on patent and trademark litigation - including pharmaceutical and biologic/biosimilar litigation under the Patented Medicines (Notice of Compliance) Regulations.
Geoff has experience in all aspects of intellectual property litigation, ranging from pre-litigation opinions to appearing before the Ontario Court, Federal Court, and Federal Court of Appeal. He has worked with counsel in other jurisdictions, including the United States, Europe and Australia, to co-ordinate the Canadian part of multi-jurisdictional lawsuits.
Geoff speaks frequently on patent litigation, intellectual property law, and developments related to pharmaceuticals, biologics/biosimilars, biotechnology and medical devices, subjects on which he has also published extensively. Geoff is the Chair of the Canadian Bar Association Biotechnology Committee, and regularly lectures at the Masters of Biotechnology program at the University of Toronto. Geoff has also lectured at Osgoode Hall Law School for the patents course.
Geoff holds a M.Sc. from the University of Toronto where his graduate work involved organic geochemistry and computer modelling. He worked for two years as a consultant at an engineering firm prior to attending law school.
About DLA Piper (Canada)
Building strong and substantial client relationships was the compass for DLA Piper’s business strategy and future development. Today, we are located in more than 30 countries throughout Africa, the Americas, Asia Pacific, Europe and the Middle East, positioning us to help companies with their legal needs around the world.
Our clients range from multinational, Global 1000 and Fortune 500 enterprises to start-up companies developing industry-leading technologies. They include more than half of the Fortune 250 and nearly half of the FTSE 350 or their subsidiaries.
With over 260 Canadian lawyers delivering services in more than 50 practice areas, DLA Piper Canada provides unparalleled value to our clients by combining the deep resources of a global firm with the highest level of personal service in the business. Our mission and vision is to be Canada’s premiere entrepreneurial full service law firm known for its leading edge specialties and comprised of lawyers who achieve results that exceed expectations through commitment to our clients and ourselves.
Abstract
The development of biosimilars is increasing at a dynamic pace globally, and the biosimilar landscape in each jurisdiction is constantly evolving. Biosimilars offer improved access to effective biological therapies at reduced costs, which is one of the reasons why biosimilars continue to garner great interest among industry, regulators and consumers. At this point, many biopharmaceutical companies are looking for up-to-date guidance to understand the regulatory and legal landscapes for biosimilars in the United States, in Canada and in Europe.
In this two-hour live webcast, a panel of distinguished professionals and thought leaders organized by The Knowledge Group will provide an in-depth discussion on the regulatory and legal developments that biosimilar companies should know. Our speakers will share practical advice to succeed in this rapidly developing area of the drug industry.
Some of the major topics that will be covered in this course are:
- Biosimilar Legislation in the US
- The Purple Book of Biosimilars
- US Approval Pathways
- Interchangeability Requirements
- Biosimilar Approval Pathway in Canada
- Ongoing Regulatory and Legislative changes in Canada
- Litigation Landscape in Canada
- Existing Guidelines in Europe
- Review of Approvals in Europe
- Recent Regulatory and Legal Updates
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/
For further details, please visit: https://theknowledgegroup.org/event-homepage/?event_id=2001
About Geoffrey D. Mowatt
Geoffrey Mowatt is certified by the Law Society of Upper Canada as a Specialist in Patent Law. His practice encompasses all areas of intellectual property law, with a focus on patent and trademark litigation - including pharmaceutical and biologic/biosimilar litigation under the Patented Medicines (Notice of Compliance) Regulations.
Geoff has experience in all aspects of intellectual property litigation, ranging from pre-litigation opinions to appearing before the Ontario Court, Federal Court, and Federal Court of Appeal. He has worked with counsel in other jurisdictions, including the United States, Europe and Australia, to co-ordinate the Canadian part of multi-jurisdictional lawsuits.
Geoff speaks frequently on patent litigation, intellectual property law, and developments related to pharmaceuticals, biologics/biosimilars, biotechnology and medical devices, subjects on which he has also published extensively. Geoff is the Chair of the Canadian Bar Association Biotechnology Committee, and regularly lectures at the Masters of Biotechnology program at the University of Toronto. Geoff has also lectured at Osgoode Hall Law School for the patents course.
Geoff holds a M.Sc. from the University of Toronto where his graduate work involved organic geochemistry and computer modelling. He worked for two years as a consultant at an engineering firm prior to attending law school.
About DLA Piper (Canada)
Building strong and substantial client relationships was the compass for DLA Piper’s business strategy and future development. Today, we are located in more than 30 countries throughout Africa, the Americas, Asia Pacific, Europe and the Middle East, positioning us to help companies with their legal needs around the world.
Our clients range from multinational, Global 1000 and Fortune 500 enterprises to start-up companies developing industry-leading technologies. They include more than half of the Fortune 250 and nearly half of the FTSE 350 or their subsidiaries.
With over 260 Canadian lawyers delivering services in more than 50 practice areas, DLA Piper Canada provides unparalleled value to our clients by combining the deep resources of a global firm with the highest level of personal service in the business. Our mission and vision is to be Canada’s premiere entrepreneurial full service law firm known for its leading edge specialties and comprised of lawyers who achieve results that exceed expectations through commitment to our clients and ourselves.
Abstract
The development of biosimilars is increasing at a dynamic pace globally, and the biosimilar landscape in each jurisdiction is constantly evolving. Biosimilars offer improved access to effective biological therapies at reduced costs, which is one of the reasons why biosimilars continue to garner great interest among industry, regulators and consumers. At this point, many biopharmaceutical companies are looking for up-to-date guidance to understand the regulatory and legal landscapes for biosimilars in the United States, in Canada and in Europe.
In this two-hour live webcast, a panel of distinguished professionals and thought leaders organized by The Knowledge Group will provide an in-depth discussion on the regulatory and legal developments that biosimilar companies should know. Our speakers will share practical advice to succeed in this rapidly developing area of the drug industry.
Some of the major topics that will be covered in this course are:
- Biosimilar Legislation in the US
- The Purple Book of Biosimilars
- US Approval Pathways
- Interchangeability Requirements
- Biosimilar Approval Pathway in Canada
- Ongoing Regulatory and Legislative changes in Canada
- Litigation Landscape in Canada
- Existing Guidelines in Europe
- Review of Approvals in Europe
- Recent Regulatory and Legal Updates
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/
Contact
The Knowledge Group
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Contact
Categories